NPPB and heart failure: For patients without baseline heart failure risks, such as baseline B-type natriuretic peptide (BNP) levels >200 pg/mL and a history of hospitalization for heart failure, the risk for heart failure among bardoxolone methyl−treated and placebo-treated patients was similar (2%) [165,166].